Please login to the form below

Not currently logged in
Email:
Password:

amyloid

This page shows the latest amyloid news and features for those working in and with pharma, biotech and healthcare.

Biogen and Eisai claim mid-stage win for Alzheimer’s drug

Biogen and Eisai claim mid-stage win for Alzheimer’s drug

well as reduction in amyloid deposits in the brain, at the 18-month timepoint. ... and beta-amyloid levels, backed up by a dose-response relationship, write the analysts.

Latest news

More from news
Approximately 12 fully matching, plus 122 partially matching documents found.

Latest Intelligence

  • Integrating digital biomarkers into precision medicine Integrating digital biomarkers into precision medicine

    Examples of digital biomarker usage cases include:. Using an interactive app to pre-screen potential study participants; for instance, a game to assess cognitive ability as a predictor of beta-amyloid

  • Holding on to hope for Alzheimer’s advances Holding on to hope for Alzheimer’s advances

    All highly disappointing for Lilly (which saw its stock sink), for academics that backed the amyloid hypothesis and for patients. ... Professor Peter Roberts at the University of Bristol is one of those who feels that the amyloid card has been overplayed.

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    development agreement with AstraZeneca for a phase I antibody selective for amyloid-beta 42 in Alzheimer's disease.

  • Pharma deals during January 2014 Pharma deals during January 2014

    The original deal was forged back in 2012 when Genzyme gained access to patisiran for the treatment of transthyretin familial amyloid polyneuropathy in Japan and other Asian markets.

  • Interview: Mike Hutton, Lilly Interview: Mike Hutton, Lilly

    Lilly's great hope in amyloid beta is now solanezumab, a candidate with a chequered history. ... I think Amyloid-beta will be a very powerful approach for early-stage disease, for delaying the onset of symptoms and their progression.

More from intelligence
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon

    The firm focuses on brain health, memory and ageing and its lead product is an oral amyloid aggregation inhibitor that targets Alzheimer's disease. ... Alzheon's founder, president and chief executive officer Martin Tolar said: “ JP will provide

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics